title: Methodological matters on an Alzheimer's dementia trial: is a double-blind randomized controlled study design sufficient to draw strong conclusions on treatment? Reply to Dr Mazza and colleagues.
authors: S
authors: S
authors: Corrao
authors: R
authors: R
authors: Scaglione
authors: L
authors: L
authors: Calvo
authors: G
authors: G
authors: Licata
mesh_terms: D000544:Alzheimer Disease / Q000150:complications / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003704:Dementia / Q000150:complications / Q000188:drug therapy*; D000077265:Donepezil; D004311:Double-Blind Method; D020441:Ginkgo biloba; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil